Over the last 10 years, gene therapy for biallelic RPE65-mediated inherited retinal dystrophy has been the subject of many clinical trials, leading to the first United State Food and Drug Administration (US FDA)-approved ocular gene therapy for the treatment of an inherited retinal disorder. This evidence concerns the gene RPE65 and inherited retinal dystrophy.